Nanotube Injector Transfers Cytoplasmic Contents and Organelles Between Living Cells Safely

Why It Matters

The injector enables scalable, high‑viability cytoplasmic engineering, opening new possibilities for cell‑based therapies, disease modeling, and drug screening without genetic modification.

Key Takeaways

• Nanotube injector achieves >90% cytoplasmic transfer efficiency.
• Cell viability remains around 95% after injection.
• Functional mitochondria delivered boost recipient ATP production.
• Pressure‑controlled nanotube pores minimize membrane damage.
• Platform enables scalable, non‑genetic cell engineering.

Pulse Analysis

The exchange of proteins, DNA, and organelles between neighboring cells is a fundamental biological process that shapes development, stress response, and tissue repair. Traditional approaches to manipulate the cytoplasmic milieu—such as detergent‑based lysis, ultrasound disruption, lipid carriers, or microinjection—either destroy the target cell, suffer low throughput, or are limited to small molecules. In this context, the nanotube‑based injector unveiled by Professor Takeo Miyake’s team at Waseda University represents a paradigm shift, offering a physical conduit that pierces the plasma membrane without compromising cell integrity. The device consists of a gold membrane studded with vertically aligned nanotubes attached to a glass tube that can be pressurized.

By fine‑tuning air pressure, nanotube diameter, and density, researchers can aspirate cytoplasm from donor cells and dispense it into recipients with microliter‑scale buffer flows. Experimental data show more than 90 % transfer efficiency while maintaining roughly 95 % cell viability. Crucially, the system successfully transports whole mitochondria; recipient cells exhibit markedly higher ATP levels, confirming that the organelles remain functional after passage through the nanoscopic channels.

These capabilities open new avenues for regenerative medicine and precision biotechnology. Therapies that rely on cell transplantation could be pre‑conditioned with healthy mitochondria or cytoplasmic factors, potentially improving metabolic performance without altering the genome. Likewise, disease‑modeling platforms and high‑content drug screens can benefit from rapid, reproducible cytoplasmic swapping to generate more physiologically relevant cell populations. As the technology matures, integration with automated robotics may enable large‑scale cell engineering, positioning the nanotube injector as a cornerstone tool for next‑generation cell‑based therapeutics.